<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011996</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_107</org_study_id>
    <nct_id>NCT03011996</nct_id>
  </id_info>
  <brief_title>To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration</brief_title>
  <official_title>An Open-label, Randomized Study to Evaluate Pharmacokinetic Interaction, Pharmacodynamics and Safety After Multiple Oral Dosing of CJ-12420 and Amoxicillin/Clarithromycin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort 1

      To evaluate the pharmacokinetic interactions of CJ-12420 after multiple oral doses of
      CJ-12420 given alone or in combination with amoxicillin/clarithromycin in healthy subjects.

      Cohort 2

      To evaluate the pharmacodynamic profiles of CJ-12420 after multiple oral doses of CJ-12420 in
      combination with amoxicillin/clarithromycin in healthy subjects as compared to an active
      control group, i.e., pantoprazole in combination with amoxicillin/clarithromycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the pharmacokinetic the drug-drug interaction of CJ-12420 and
      amoxicillin/clarithromycin and investigate the pharmacodynamic of co-administration of
      CJ-12420 and amoxicillin and clarithromycin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of CJ-12420, clarithromycin and amoxicillin</measure>
    <time_frame>Up to 120 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of CJ-12420, clarithromycin and amoxicillin</measure>
    <time_frame>Up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentraion(tmax) of CJ-12420, clarithromycin and amoxicillin</measure>
    <time_frame>Up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life(t1/2) of CJ-12420, clarithromycin and amoxicillin</measure>
    <time_frame>Up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance at steady state(CLss/F) of CJ-12420, clarithromycin and amoxicillin</measure>
    <time_frame>Up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state(Vdss/F) of CJ-12420, clarithromycin and amoxicillin</measure>
    <time_frame>Up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median pH</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Data from the pH probe monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at pH &gt; 3 (%)</measure>
    <time_frame>Day -1, Day 1, Day 7 up to 24 hours</time_frame>
    <description>the percent of time the pH as data from the pH probe monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at pH &gt; 4 (%)</measure>
    <time_frame>Day -1, Day 1, Day 7 up to 24 hours</time_frame>
    <description>the percent of time the pH as data from the pH probe monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at pH &gt; 6 (%)</measure>
    <time_frame>Day -1, Day 1, Day 7 up to 24 hours</time_frame>
    <description>the percent of time the pH as data from the pH probe monitoring</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Drug Interaction</condition>
  <condition>Pharmacokinetic</condition>
  <condition>Pharmacodynamic</condition>
  <arm_group>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 100mg BID for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 50mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole 40mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 100mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLR 500mg/AMX 1g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLR 500mg/AMX 1g BID for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 100mg + CLR 500mg/AMX 1g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLR 500mg</intervention_name>
    <description>Cohort 1: bid for 5 days Cohort 2: bid for 7 days</description>
    <arm_group_label>CJ-12420 50mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_label>Pantoprazole 40mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_label>CJ-12420 100mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_label>CLR 500mg/AMX 1g</arm_group_label>
    <arm_group_label>CJ-12420 100mg + CLR 500mg/AMX 1g</arm_group_label>
    <other_name>Clarithromycin 500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 100mg</intervention_name>
    <description>Cohort 1: bid for 5 days Cohort 2: bid for 7 days</description>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <arm_group_label>CJ-12420 100mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_label>CJ-12420 100mg + CLR 500mg/AMX 1g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 50mg</intervention_name>
    <description>Cohort 2: bid for 7 days</description>
    <arm_group_label>CJ-12420 50mg + CLR 500mg + AMX 1g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMX 1g</intervention_name>
    <description>Cohort 1: bid for 5 days Cohort 2: bid for 7 days</description>
    <arm_group_label>CJ-12420 50mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_label>Pantoprazole 40mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_label>CJ-12420 100mg + CLR 500mg + AMX 1g</arm_group_label>
    <arm_group_label>CLR 500mg/AMX 1g</arm_group_label>
    <arm_group_label>CJ-12420 100mg + CLR 500mg/AMX 1g</arm_group_label>
    <other_name>Amoxicillin 1g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40mg</intervention_name>
    <description>Cohort 2: bid for 7 days</description>
    <arm_group_label>Pantoprazole 40mg + CLR 500mg + AMX 1g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers aged ≥19 and ≤45 years at screening;

          2. No congenital or chronic disease, and no morbid symptoms or findings on screening
             tests;

          3. Body mass index (BMI) ≥18.5 and ≤28 kg/m2;

          4. Considered eligible based on medical examinations (including interview, vital signs,
             12-lead ECG, physical exam and laboratory tests) which are set and performed in
             accordance with the nature of investigational product by the investigator;

          5. Voluntary consent to participate in the study after being fully informed of purpose
             and procedures of the study, and profiles of investigational product prior to the
             participation;

          6. For Cohort 2, positive on 13C urea breath test.

        Exclusion Criteria:

          1. Medical history

               1. History or current evidence for diseases considered clinically relevant by the
                  investigator including hepatic, renal, gastrointestinal, respiratory,
                  musculoskeletal, endocrine, neurologic, hemato-oncological, urinary, or
                  cardiovascular (including cardiac arrhythmia) diseases;

               2. History of gastrointestinal diseases (such as gastritis, gastrodynia,
                  gastroesophageal reflux disease, Crohn's disease and ulcer) or abdominal surgery
                  (except for simple appendectomy or herniotomy) which are considered to have
                  potential effect on drug absorption by the investigator;

               3. For Cohort 2, previous treatment failure for H. pylori eradication.

          2. Laboratory tests and ECG

               1. AST or ALT ≥ 1.25 x upper limit of normal (ULN);

               2. Total bilirubin ≥ 1.5 x ULN;

               3. eGFR calculated by CKD-EPI formula &lt; 80 mL/min;

               4. Any clinically relevant ECG abnormalities.

          3. Allergy and drug abuse

               1. History of hypersensitivity to drugs containing investigational products
                  (penicillins, cephems, macrolides, pantoprazole and benzimidazole) and other
                  drugs (including aspirin and antibiotics);

               2. History of drug abuse or positive on drug screening test.

          4. Drug/dietary restrictions

               1. Medications (including herbal supplements) or abnormal diet (e.g., grapefruit
                  juice &gt; 1 L/day, excessive garlic, broccoli, kale, etc.) which may have effect on
                  absorption, distribution, metabolism and excretion of investigational products
                  within 28 days prior to the first study dose;

               2. Use of prescription drugs, over-the-counter drugs (OTCs) or vitamins within 10
                  days prior to the first study dose;

               3. Participating in other study and receive investigational product within 3 months
                  prior to the first study dose.

          5. Blood donation and transfusion

               1. Whole blood donation within 60 days prior to the first study dose;

               2. Donation of blood components or transfusion within 30 days prior to the first
                  study dose.

          6. Pregnancy and contraception

               1. Pregnant or breast-feeding;

               2. Subject or his partner's inability to use of medically qualifying
                  dual-contraceptive methods or medically acceptable contraception (including
                  intrauterine device with established pregnancy failure rate, barrier methods with
                  spermicide, vasectomy, tubectomy, tubal ligation and hysterectomy) from screening
                  to 30 days of the last dose of investigational product.

          7. Others

               1. Heavy use of alcohol (average alcohol intake ≥30 g/day) or positive on alcohol
                  test;

               2. Heavy smoker (&gt;10 cigarettes/day);

               3. Caffeine intake &gt; 400 mg/day;

               4. Any clinically relevant findings considered inappropriate for study participation
                  at the discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje university college of medicine Busan Paik Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Baik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

